Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alphaASGR1-RSPO2-RA
- Development stage
- Preclinical
- Lead developer
- Surrozen
- Modality
- Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**alphaASGR1-RSPO2-RA** is an experimental hepatocyte-targeted R-spondin mimetic protein designed to selectively enhance Wnt signaling in the liver. It consists of an anti-ASGR1 antibody fused to a mutant RSPO2 domain engineered to eliminate LGR4-6 binding while preserving binding to the Wnt negative regulators ZNRF3 and RNF43, thereby promoting stabilization of Wnt receptors and amplifying endogenous Wnt pathway activity specifically in ASGR1-expressing hepatocytes. Preclinical studies showed liver-selective induction of Wnt target genes, hepatocyte proliferation, and improved liver function in mouse models of liver injury, positioning it as a regenerative biologic concept for liver diseases. The molecule appears to be a research-stage predecessor or prototype related to later Surrozen hepatocyte-targeted RSPO mimetics such as SZN-043.
- Other names
- αASGR1-RSPO2-RAanti-ASGR1 antibody-mutant RSPO2 fusion proteinanti-ASGR-1 antibody-mutant RSPO2 fusion proteinanti-ASGR 1 antibody-mutant RSPO2 fusion proteintissue-targeted R-spondin mimetic
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)ZNRF3 (Zinc and ring finger protein 3)RNF43 (Ring finger protein 43)
Beyond the preview
Go deeper on alphaASGR1-RSPO2-RA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alphaASGR1-RSPO2-RA.